ReviewF1000Research2016
Understanding nontuberculous mycobacterial lung disease: it's been a long time coming.
Review in F1000Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Accuracy of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Mycobacteria: a systematic review and meta-analysis.Scientific reports · 2018Pooled it
- A Successfully Treated Case ofInfection and drug resistance · 2026Article
- The diagnostic value of third-generation nanopore sequencing in non-tuberculous mycobacterial infections.Frontiers in cellular and infection microbiology · 2025Article
- Oral oxaborole MRX-5 exhibits efficacy against pulmonaryAntimicrobial agents and chemotherapy · 2024Article
- Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease.Nature reviews. Drug discovery · 2024Review
- Self-recycling and partially conservative replication of mycobacterial methylmannose polysaccharides.Communications biology · 2023Article
- Polymer-Antimicrobial Peptide Constructs with Tailored Drug-Release Behavior.Pharmaceutics · 2023Article
- Evaluation of the Efficiency of Random and Diblock Methacrylate-Based Amphiphilic Cationic Polymers against Major Bacterial Pathogens Associated with Cystic Fibrosis.Antibiotics (Basel, Switzerland) · 2023Article
- Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue.The Journal of experimental medicine · 2022Article
- Combining comparative genomic analysis with machine learning reveals some promising diagnostic markers to identify five common pathogenic non-tuberculous mycobacteria.Microbial biotechnology · 2021Article
- The lung microbiota in Korean patients with non-tuberculous mycobacterial pulmonary disease.BMC microbiology · 2021Article
- TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus.Antimicrobial agents and chemotherapy · 2020Article
- Nontuberculous Mycobacteria Show Differential Infectivity and Use Phospholipids to Antagonize LL-37.American journal of respiratory cell and molecular biology · 2020Article
- Antibacterial activity of high-dose nitric oxide against pulmonaryAccess microbiology · 2020Article
- Sodium Hyaluronate Nanocomposite Respirable Microparticles to Tackle Antibiotic Resistance with Potential Application in Treatment of Mycobacterial Pulmonary Infections.Pharmaceutics · 2019Article
- Infection Source and Epidemiology of Nontuberculous Mycobacterial Lung Disease.Tuberculosis and respiratory diseases · 2019Review
- Review
- Multiplex cytokine analysis in Mycobacterium avium complex lung disease: relationship between CXCL10 and poor prognostic factors.BMC infectious diseases · 2019Article
- Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report.Annals of the American Thoracic Society · 2018Article
- Sputum Detection of Predisposing Genetic Mutations in Women with Pulmonary Nontuberculous Mycobacterial Disease.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With a surprising predictability, most studies and reviews addressing therapy for nontuberculous mycobacterial (NTM) lung disease either start or end by mentioning the paucity of data from randomized and controlled trials. That is a legitimate criticism for NTM lung disease therapy, but it also somehow seems to influence attitudes toward all aspects of NTM investigation. Certainly the study of NTM diseases in general and NTM lung disease in particular is a recent development. Previously, NTM were viewed as minor, if inconvenient, pathogens similar to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.